Despite many years of meticulous immunophenotyping of childhood acute lymphoblastic leukaemia (ALL) cases the prognostic significance of some subtypes remains unclear. The Medical Research Council UKALLXI trial (1990)(1991)(1992)(1993)(1994)(1995)(1996) in which uniform treatment has been given to 2090 children with ALL below the age of 18 years and above the age of 1 year, has afforded the opportunity to review these issues. Children with ALL of mature B cell type were not entered into this trial. Immunophenotype analysis was performed in each individual trial centre, but results were centrally reviewed in all cases, and were both available and considered adequate in 1934 (93%) of the first 2090 patients entered. The main diagnostic categories were early pre-B or null reported in 60 cases (3.1%), common ALL in 1242 (64.2%), pre-B in 252 (13.0%), 'common' or pre-B in 172 (8.9%) and T cell in 207 (10.7%) cases. Children with T cell disease were significantly more likely to be over the age of 10 years, with central nervous system disease at diagnosis and to be CD34 negative. They also had a higher incidence of high white cell count and were more likely to be of the FrenchAmerican-British (FAB) L2 morphological subtype. Patients with 'null' cell disease tended to be less than 2 years or greater than 10 years of age, and CD13 and CD33 positive. CD10 was associated with lower white cell count (WBC) at diagnosis, younger age and FAB L1 morphological subtype. The presence of cytoplasmic immunoglobulin in pre-B cells was not associated with any specific clinical or laboratory features. CD34 positivity was less common in T cell patients and was associated with low WBC. Disease-free survival (DFS) and 95% confidence intervals (CI) at 5 years from diagnosis was 52% (95% CI: 44-59%) for T cell disease, 58% (95% CI: 43-73%) for early pre-B (or null cell) disease and 65% (95% CI: 62-68%) for common or pre-B disease; there being no significant difference between common and pre-B disease with regard to disease outcome. Patients with T cell disease had a worse prognosis than any other immunophenotype group (P Ͻ 0.00005). However this worse outcome was no longer significant after allowing for the other principal prognostic factors of age, gender and white cell count at diagnosis except for the very small number with WBC Ͻ20 × 10 9 /l and T cell disease. Those with CD10-positive leukaemia did better than those who were CD10 negative (P Ͻ 0.00005), with DFS at 5 years 64% (95% CI: 62-67%) for positive vs 56% (95% CI: 49-62%) for CD10 negative. CD10 positivity did not have independent significance when white count, gender and age were taken into account. CD13, CD33, and cytoplasmic positivity carried no prognostic significance. Keywords: immunophenotype; prognosis; acute lymphoblastic leukaemia (ALL); children
Introduction
Immunological heterogeneity of ALL has been recognised for many years. 1 With some notable exceptions the clinical significance of subtypes remains unclear. [2] [3] [4] [5] In recent years, dur- ing which time the use of standardised panels of antibodies has permitted allocation of more than 98% of leukaemias to their respective lineage, 6, 7 little evidence has emerged to suggest that immunophenotype-directed therapy altered the outcome of disease, except in ALL of mature B cell type where intensive lymphoma-like protocols have greatly improved the outcome. 8, 9 As part of the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI) we wished to clarify, using a standard panel of antibodies, the incidence of subtype, their clinical associations and the prognostic significance of specific markers.
Patients and methods
A total of 2090 children between the ages of 12 months and 18 years were entered into the MRC UKALLXI therapy trial between October 1990 and 31 March 1997. Follow-up is to 31 October 1997, giving a median follow-up time of 40 months. The randomised questions asked by the trial relate to the most appropriate type of central nervous system directed therapy, and whether or not three intensive blocks of therapy given during the period of apparent complete remission were superior to the standard two intensification blocks carried forward from the previous MRC UKALLX trial. 10 Patients over the age of 1 year were eligible for entry into the trial if they had ALL of any category apart from mature B cell (surface membrane immunoglobulin positive), for whom there was an alternative protocol. Centres admitting patients to the trial were requested to perform a standard panel of immunophenotyping tests including anti-CD2, CD7, CD10, CD13, CD19, CD33, CD34, HLA-DR, terminal deoxynucleotidyl transferase (tdt) and cytoplasmic immunoglobulin staining (cyt ).
Children were classified into six main immunophenotype groups depending on the presence of the following antibody correlations.
(1) Early pre-B or null: CD10 negative, CD19 positive, TDT positive and negative for T cell markers. (2) Common ALL: CD10 positive, CD19 positive, TDT positive and T cell marker negative. (3) Pre-B: the same as common but also cytoplasmic immunoglobulin positive. (4) T cell disease was classified as CD2 and/or CD7 positive but CD19 and HLA-DR negative. (5) Finally, an 'unusual' category contained patients who expressed so called myeloid antigens (CD13 and/or CD33), and other patients whose antibody profile did not fit into any of the above four categories. (6) Ninety-eight patients have the features of common ALL but the cytoplasmic immunoglobulin test was not performed and these cases were classified as common or pre-B. We used a cut-off point for positivity at 20% (or above) of positively reacting cells for CD10, CD13, CD33, HLA-DR and cytoplasmic immunoglobulin and 30% for other markers.
In order to determine the methodologies used by the 98 trial participants a questionnaire was circulated and returned in 88 (90% of cases). Thirty-seven laboratories (42%) used a fluorocytometry analysis alone. Thirty-three (37.5%) used FACS and one or more other methods, and 18 (20.4%) used other methods but not fluorocytometry. A battery of monoclonal antibodies was recommended at the outset of the trial and workshops help to provide consistent quality of performance. FAB types were assigned by a central panel of three reviewers of morphology. The children were treated with a standard three-drug induction phase consisting of l-asparaginase, vincristine and prednisolone plus intrathecal methotrexate on days 1, 8 and 28. At the beginning of both the 5th and the 20th week all patients received a 5 day intensive block of therapy which consisted of the following drugs: vincristine, prednisolone, etoposide, cytarabine, daunorubicin, thioguanine and intrathecal methotrexate as previously described for UKALLX. 10 Patients with blood white cell counts at diagnosis of greater than 50 × 10 9 /l were randomly assigned to receive three intrathecal doses of methotrexate either with cranial irradiation (24 Gy) or with three doses of high-dose systemic methotrexate 6-8 g/m 2 (depending on age above or below aged 4) and intrathecal methotrexate continuing every 12 weeks for 2 years. Patients with a lower white cell count (less than 50 × 10 9 /l) were randomly assigned to receive three intrathecal doses of methotrexate either with high-dose methotrexate or alone, both followed by 12 weekly intrathecal methotrexate. Until March 1992, all patients were also eligible for randomisation between one and two blocks of intensive therapy. After that time, all patients received at least two blocks and were randomly assigned to receive a third block or not, the third block beginning at the 35th week and extending over an 8-week period. CNS disease at diagnosis was defined as a blast cell count in the day 1 lumbar CSF of at least 5 per cubic mm with or without cranial nerve palsy.
Associations between immunophenotype and characteristics at diagnosis were examined using 2 tests or Fisher's exact test when the numbers in the groups were small. The influence of factors on disease-free survival were tested by the log rank method. 11 End points for disease-free survival were relapse, death during disease remission and induction failure. Induction failure was counted as an event on day 1. All P values quoted are two-sided.
Results
Immunophenotype analysis was available and adequate in 1934 out of the 2090 eligible patients (93% of cases). In 315 cases (16.3%) a designation of unusual was made, usually because of positivity with either CD13 or 33 (304 out of the 315 unusual cases). Among 1840 cases where CD13 or 33 results were known, CD13 or 33 positivity was present in 17 of the 58 (29%) early pre-B or null, in 224 out of 1203 (18%) common ALL cases, in 34 of 240 (14%) pre-B, in 23 of 145 (16%) common or pre-B cases, and in 26 out of 194 (13%) of T cell cases.
The correlation of immunophenotype and specific antibody positivity with age, WBC at presentation, gender, FAB morphological subtype and CNS disease at presentation was analysed (see Tables 1 and 2 ). No significant differences were found between the common and pre-B groups, so all of the CD10 plus CD19-positive patients were analysed together.
Children with null cell disease were more commonly less than 2 years of age or older than 10 years (P Ͻ 0.00005), but there were no other demonstrable associations with the factors analysed. Common and pre-B patients were younger (P Ͻ 0.00005), had lower white cell counts (P Ͻ 0.00005), were commonly of L1 FAB type (P Ͻ 0.00005) and less frequently had CNS disease at diagnosis (P = 0.0007). Patients with T cell disease were older (P Ͻ 0.00005) with higher white count (P Ͻ 0.00005), were more likely to be of FAB L2 type (P Ͻ 0.00005) and to have CNS disease at diagnosis (P Ͻ 0.00005). CD10 positivity was less common in T cell disease (P Ͻ 0.00005) and was associated with young age (P Ͻ 0.00005) and lower white count (P Ͻ 0.00005), L1 subtype (P Ͻ 0.00005) and negativity for CNS disease at diagnosis (P Ͻ 0.002). CD13 and CD33 were associated with lower white count (P = 0.008, 0.005, respectively). Cytoplasmic immunoglobulin displayed no clinical associations. CD34 positivity was less common in T cell patients (P Ͻ 0.00005) and was associated with low white count (P Ͻ 0.0005).
Disease-free survival at 5 years for the whole of the UKALL XI trial was 63% (95% CI: 61-66%); overall survival at 5 years was 85% (95% CI: 83-87%). The results of an analysis of immunophenotype and specific antibody positivity as prognostic features for outcome of the leukaemia are shown in Table 3 and in Figures 1-3 . Patients with T cell disease did considerably worse than those with early B cell lineage phenotypes (null, common or pre-B, P Ͻ 0.00005) for diseasefree survival (DFS). The worse outcome for the T cell patients was not significant (P = 0.2) when age, gender and white count were allowed for. However, a test for trend over WBC group showed an increasing effect of T cell disease with lower WBC (P = 0.00002). Among patients with WBC Ͻ20 × 10 9 /l, the small number of T cell patients (37 out of 1174) fared worse with a 5-year DFS of 47% (95% CI: 30-63%) vs 69% (95% CI: 66-73%) for non T cell. DFS and 5% confidence interval (CI) at 5 years from diagnosis was 52% (95% CI: 44-59%) for T cell disease, 58% (95% CI: 43-73%) for early pre-B or null cell disease and 65% (95% CI: 62-68%) for common and pre-B disease (there being no significant difference between the common and pre-B groups).
CD10 positivity was associated with a better outcome (P Ͻ 0.00005) with DFS at 5 years 64% (95% CI: 62-67%) for CD10 positive vs 56% (95% CI: 49-62%) for CD10 negative. CD19 positivity was similarly associated with a better outcome (P Ͻ 0.00005) with DFS at 5 years 65% (95% CI: 62-68%) vs 54% (95% CI: 47-61%) for those negative. CD10 was not of independent prognostic value when age, gender and white count were taken into account. There was an apparent interaction between the effect of T cell phenotype and CD10 positivity (P = 0.01) with T cell patients faring worse in the CD10-positive group, but this was no longer apparent after allowing for the effect of age, gender and white cell count. CD13, 33 and cytoplasmic immunoglobulin positivity did not predict outcome. CD34-positive cases had a similar outcome to CD34-negative cases (DFS at 5 years 62% (95% CI: 58-67%) vs 65% (95% CI: 61-69%).
Discussion
Introduction of heterologous and then monoclonal antibody typing of acute lymphoblastic leukaemia more than two dec- There were no significant differences between common and pre-B patients. The ratio of observed to expected events is obtained from a comparison of all groups for phenotypes and from a comparison of positives vs negatives for the antibody groups. a P value -for heterogeneity. b Trend over WBC groups. + Indicates antibody positivity of the leukaemic blast cells.
Figure 1
Disease-free survival is presented for the five immunophenotype groups. Patients with T cell disease have a significantly worse disease-free survival (P Ͻ 0.00005) but this difference is not significant after allowance for the main prognostic factors, age, gender and white cell count at diagnosis.
Figure 2
Patients with T cell disease do significantly worse among those with CD10 positivity (interaction P = 0.01), but this effect is no longer seen after adjustment for age, gender and white cell count at diagnosis. ades ago proved a major step forward in verification of precise diagnosis, as evidenced by the near disappearance of the previously common but unsatisfactory diagnosis of acute undifferentiated leukaemia. 6, 7 This does not mean that immunophenotyping is the only diagnostic test of importance, or that it should be taken in isolation because morphological assessment remains crucial. 12 Another proviso is that a proportion of patients have leukaemic blasts which do not obey the ontogenic rules and disclose aberrant or asynchronous expression of antigens. 13, 14 This has been a particular problem as it has been recognised that the so-called myeloid antigens CD13 and 33 may be present on ALL blasts. [15] [16] [17] The literature suggests that the incidence of CD13 and/or CD33 positivity is in the order of 5-10% in children and in up to 20% of adult cases. 18 In the UKALLXI trial the overall incidence of such positivity among cases tested was 17%, with only 13% of T cell cases being positive and the highest incidence at 29% occurring in the early pre-B or null cell cases. It has been emphasised that these cases should be clearly differentiated from the rarer cases where two distinct myeloid and lymphoid cell populations exist, or where the cells are undifferentiated by conventional morphological and cytochemical criteria, but clearly express markers of different lineages. 19 We failed to demonstrate any independent prognostic value for the pres- ence of CD13 and 33 antigens in contrast to some other studies 20, 21 but in confirmation of the findings of other recent reports. [22] [23] [24] Recently, it has been shown that the fusion gene TEL-AML1 produced by the cryptic t(12;21) translocation is expressed in nearly two-thirds of cases of CD13-or CD33-positive acute lymphoblastic leukaemia cases in childhood. 25 At present the prognostic importance of the presence of this transcript is uncertain.
We confirmed the close association between null cell disease 23 and CD13 positivity with older age, lower white count and L1 subtype. CD33 was only linked in our series to lower white count at diagnosis.
In the UKALLXI study, none of the immunophenotyping groups using a battery of antibodies held any independent prognostic value except for the small number of low WBC patients with T cell disease. T cell patients generally fared worse as did patients who were CD10 negative, but these effects were lost when age, gender and white count were taken into account. Several recent studies have produced proposals to explain this, and have suggested that other factors, especially age, sex and white count have better predictive value, and that improving results from chemotherapy may also negate the influence of some factors. [3] [4] [5] Whatever the cause, we have investigated several sets of factors which have been proposed to have important prognostic significance, and have even been used to determine changes, particularly intensification of therapy, and found them to be valueless in this respect. Theoretically speaking, biologically different leukaemias may respond to different therapies, but at the present time this has only been clearly shown for the rare leukaemia of mature B cells, 8, 9 and other approaches must remain speculative. It is possible that further sub-classification of the immunophenotype groups, as can be done for T cell ALL with the use of CD3, CD5, CD10 etc may define specific groups with prognostic significance, [26] [27] [28] [29] [30] but it remains to be seen whether this will actually prove of value in patient management, as it has done when defining ALL of mature B cell phenotype.
We have been able to demonstrate other interesting clinical correlations. T cell patients are less likely to be CD34 positive, 31 more likely to be older, be CNS positive at diagnosis, have L2 morphology and a higher initial white count. Null cell patients tend to be less than 2 years old and more commonly CD13 and 33 positive, as well as being CD10 negative. But none of these associations are so clear cut as to be of absolute diagnostic value. They do show trends which can be useful clinically, if spurious or unusual phenotype results are obtained. However, there is no current evidence in favour of basing therapeutic plans on immunophenotyping results, even for the small group of low WBC patients with T cell disease who seem to be the only group for whom immunophenotyping may add prognostic information. This situation may of course change when more biologically specific drugs and other therapies (eg gene therapy) become available.
